Research Analysts’ Weekly Ratings Changes for RxSight (RXST)

Several brokerages have updated their recommendations and price targets on shares of RxSight (NASDAQ: RXST) in the last few weeks:

• 7/12/2026 – RxSight was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 7/7/2026 – RxSight was given a new $6.50 price target by Jefferies Financial Group Inc..
• 7/7/2026 – RxSight had its price target lowered by Bank of America Corporation from $8.00 to $6.50. They now have an “underperform” rating on the stock.
• 7/7/2026 – RxSight had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $11.00 price target on the stock.
• 6/11/2026 – RxSight was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/22/2026 – RxSight was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.